Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;29(2):317-326.
doi: 10.1016/j.soc.2019.11.005.

Overview and Current Status of Peptide Receptor Radionuclide Therapy

David L Bushnell  1 , Kellie L Bodeker  2
Affiliations
Review

Overview and Current Status of Peptide Receptor Radionuclide Therapy

David L Bushnell et al. Surg Oncol Clin N Am. 2020 Apr.

Abstract

Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment of patients with metastatic neuroendocrine tumors, delivering modest objective tumor response rates but notable survival and symptomatic benefits. The first PRRT approved by the US Food and Drug Administration was lutetium 177-DOTATATE and is for use in adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The treatment paradigm typically leads to significant improvement in symptomology coupled with an extended period of progression-free survival. Side effects are limited, with a small fraction of individuals experiencing clinically significant long-term renal or hematologic toxicity.

Keywords: Dotatate; Lu-177; Lutathera; PRRT; Radionuclide.

PubMed Disclaimer

MeSH terms

Supplementary concepts